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Summary
 
CD28 is a cell surface molecule that mediates a costimulatory signal crucial for T cell prolifera-
tion and lymphokine production. The signal transduction mechanisms of CD28 are not well
understood. Itk, a nonreceptor protein tyrosine kinase specifically expressed in T cells and mast
cells, has been implicated in the CD28 signaling pathway because of reports that it becomes
phosphorylated on tyrosines and associates with CD28 upon cross-linking of the cell surface
molecule. To determine whether Itk plays a functional role in CD28 signaling, we compared T cells
from Itk-deficient mice and control mice for their responses to CD28 costimulation. T cells de-
fective in Itk were found to be fully competent to respond to costimulation. Whereas the
CD3-mediated proliferative response was severely compromised in the absence of Itk, the cal-
cineurin-independent CD28-mediated response was significantly elevated when compared
with cells from control animals. The augmented proliferation was not due to increased produc-
tion of interleukin-2. The results suggest that Itk has distinct roles in the CD3 versus the CD28
signaling pathways. By negatively regulating the amplitude of signaling upon CD28 costimula-
tion, Itk may provide a means for modulating the outcome of T cell activation during develop-
ment and during antigen-driven immune responses.
 
I
 
nduction of T cell proliferation and effector functions re-
quires recognition by the TCR of antigen bound to
MHC molecules and subsequent induction of a signaling
cascade by way of the TCR-associated CD3 complex. In
addition, costimulatory signals are required for full activa-
tion to proceed. The major costimulatory signal has been
shown to involve the CD28 molecule (1), a transmembrane
homodimer expressed on resting and activated T cells. CD28
binds to two glycoproteins, B7-1 and B7-2, expressed on
APC (1). Using transfected cell lines expressing B7-1 or B7-2,
it has been shown that B7–CD28 interactions provide co-
stimulatory signals to T cells. A similar costimulatory signal
can also be delivered with antibody against CD28 in con-
junction with anti-TCR antibodies. CD28 ligation in the
absence of cognate antigen interaction with the TCR does
not alter immune responses and has no obvious effect on
resting T cells. However, CD28 stimulation in conjunction
with TCR stimulation can dramatically augment T cell pro-
liferation and the production of multiple cytokines (2).
The signaling pathways induced by TCR ligation have
been studied extensively (3). Cross-linking of the TCR re-
sults in the activation of CD3-associated tyrosine kinases,
which further leads to calcium mobilization, activation of
protein kinase C (PKC)
 
1
 
 and the Ras signaling cascade, and
subsequent IL-2 production and cell proliferation. However,
the signal transduction pathway for CD28 costimulation
remains poorly understood. Cross-linking of CD28 with
antibodies or with cell surface B7-1 has been reported to
result in phosphorylation of CD28 and cellular substrates,
such as phospholipase C
 
g
 
1 (PLC
 
g
 
1) (4–7). However, the
effect of CD28 cross-linking on Ca
 
2
 
1
 
 flux remains contro-
versial (8–12). The cytoplasmic region of CD28 has been
shown to associate with phosphatidylinositol 3
 
9
 
 kinase
(PI3K) (13–17). Such an association is dependent on the
 
X.C. Liao and S. Fournier should be considered co–first authors of this
study.
 
1
 
Abbreviations used in this paper: 
 
CsA, cyclosporin A; IL-2R
 
a
 
, interleukin-2
receptor 
 
a
 
 chain; JNK, c-Jun NH
 
2
 
 terminus kinase; PI3K, phosphatidyli-
nositol 3
 
9
 
 kinase; PKC, protein kinase C; PLC
 
g
 
1, phospholipase C
 
g
 
1.
  
222
 
CD28 Costimulation in Itk-deficient Mice
 
SH2 domain of the p85 subunit of PI3K and on phosphor-
ylation of a tyrosine residue in the CD28 cytoplasmic do-
main. The identity of the kinase that phosphorylates CD28 af-
ter antigen stimulation remains unknown. Furthermore,
the functional significance of PI3K association with CD28
remains unresolved (18–22).
Another molecule reported to associate with CD28 is
the nonreceptor protein tyrosine kinase Itk, which is ex-
pressed specifically in T cells, mast cells, and human NK
cell lines (23–27). After cross-linking of CD28 on human
T cells, Itk has been shown to associate with the CD28
molecule and to become phosphorylated on tyrosines (28).
To determine whether this association reflects a functional
role for Itk in CD28 signaling, we compared T cells from
Itk-deficient mice (27) and control mice for responses to
CD28 costimulation. In T cells lacking Itk, the prolifera-
tive response to CD28-mediated costimulation was found
not only to be intact, but also to be markedly elevated.
Thus, in contrast with its requirement for efficient TCR-
mediated signal transduction, Itk appears to regulate nega-
tively the amplitude of the proliferative responses to CD28
costimulation, thereby providing a means to modulate the
strength and potentially the outcome of T cell activation.
 
Materials and Methods
 
Antibodies.
 
Monoclonal antibodies used for immunofluores-
cence staining have been described (27). Antibodies used for cell
purification include anti-HSA (M1/69), anti-CD8
 
a
 
 (53-6.72 and
3.155), anti-I-A
 
b,d
 
 (28-16-8S), anti-I-A
 
b,d,j,p,q,u
 
 (BP107), anti-rat
immunoglobulins, and anti-mouse immunoglobulins (American
Type Culture Collection, Rockville, MD). Antibodies used in cell
culture include anti-CD3 (500A2 for Figs. 1, 2, 4, and 145-2C11
for Fig. 3), anti-CD28 (37.51), anti-CTLA-4 (9H10), anti-IL-2
(S4B6), anti-IL-2R
 
a
 
 (3C7), and anti-IL-4 (11B11) (PharMingen,
San Diego, CA). Antibodies used in the IL-2 ELISA include the
capture mAb JES6-1A12 and the detecting mAb JES6-5H4 (Phar-
Mingen, San Diego, CA).
 
Mice.
 
Itk-deficient mice have been described (27). Litter-
mates of 
 
itk
 
1
 
/
 
2
 
 and 
 
itk
 
2
 
/
 
2
 
 (50:50% contribution of the C57Bl/6
and 129/Sv backgrounds) were used in experiments shown in
Figs. 1, 2, and 4. Experiments in which 
 
itk
 
2
 
/
 
2
 
 mice were com-
pared with age-matched B6 animals (Fig. 3) were performed with
mutant mice that had undergone a further five generations of
backcrosses to C57Bl/6.
 
Cell Purification.
 
Lymph node cells were harvested from the
mice. B cells, CD8
 
1
 
 T cells, and adherent cells were depleted by
negative selection, using nylon wool columns followed by anti-
bodies coupled to magnetic beads as described before (27), or us-
ing complement killing followed by anti-immunoglobulin pan-
ning (29). The resulting cells were 85–90% CD4
 
1
 
 from 
 
itk
 
1
 
/
 
1
 
 or
 
itk
 
1
 
/
 
2
 
 mice and 75-90% CD4
 
1
 
 from 
 
itk
 
2
 
/
 
2
 
 mice. The reason for
a consistently lower purity of 
 
itk
 
2
 
/
 
2
 
 cells is likely due to the fact
that 
 
itk
 
2
 
/
 
2
 
 mice had a significantly reduced proportion of CD4
 
1
 
T cells (27).
Cell isolation and activation was done in RPMI 1640 with
10% FCS, 2 mM 
 
l
 
-glutamine, 100 
 
m
 
M nonessential amino acids,
50 
 
m
 
M 
 
b
 
-mercaptoethanol, 110 
 
m
 
g/ml sodium pyruvate, 50 U/
ml penicillin, and 50 
 
m
 
g/ml streptomycin.
 
Stimulation with Plate-bound Anti-CD3.
 
Round-bottomed 96-
well microtiter plates were coated overnight at 4
 
8
 
C with purified
anti-CD3 mAb (500A.2) at different concentrations (from 0.025–
12 
 
m
 
g/ml). Before addition of cells, the plates were washed exten-
sively with PBS and incubated with the medium. For each well
of the 96-well plates, 5 
 
3
 
 10
 
4
 
 CD4
 
1
 
 T cells were cultured in a fi-
nal volume of 200 
 
m
 
l. Anti-CD28 (37.51) ascites was used at
1:500, 1:1,000 or 1:3,000, depending on the batch. For some ex-
periments, culture supernatants were used at 1:6.7 for CTLA-4Ig,
1:4 for anti-IL-2 (S4B6), and 1:200 for anti-IL-2R (PC61). Re-
combinant human IL-2 (PharMingen, San Diego, CA) was used
at 100 U/ml.
Cells were stimulated for 24, 48, 72, or 96 h before 50 ml of
culture supernatant were removed and 1 
 
m
 
Ci of [
 
3
 
H]thymidine
(in 50 
 
m
 
l medium) was added for 16–20 h. Cells were then har-
vested with a LS6000IC harvester (Beckman Instruments, Fuller-
ton, CA).
 
Stimulation with Antibodies Coated on Beads.
 
Polystyrene beads
were coated with anti-CD3 (1.5 
 
m
 
g/ml 500.A2) in the absence or
presence of anti-CD28 (1.5 
 
m
 
g/ml 37.51), anti–CTLA-4 (1.5 
 
m
 
g/
ml 9H10), or a combination of anti-CD28 and anti–CTLA-4.
Isotype-matched hamster mAb (536) was used to maintain a final
protein concentration of 5 
 
m
 
g/ml (30). Typically, 10 
 
m
 
l of beads
were added to 190 
 
m
 
l of 5 
 
3
 
 10
 
4
 
 cells in round-bottomed 96-
well plates. Cells were stimulated for 24, 48, or 72 h before addi-
tion of 1 
 
m
 
Ci [
 
3
 
H]thymidine (in 10 
 
m
 
l medium) and harvested 16 h
later with a Matrix 9600 harvester (Packard Instrument, Meri-
den, CT).
 
Stimulation with PMA and/or Ionomycin.
 
When PMA and/or
ionomycin were used in conjunction with anti-CD28 antibodies,
cells were cultured in 96-well flat-bottomed microtiter plates.
Anti-CD28 mAb was used at 1:3,000 for the ascites, and 2.5 
 
m
 
g/ml
for the purified antibody, unless otherwise noted. Anti-CD3 mAb
(145-2C11) was used at 2.5 
 
m
 
g/ml unless otherwise noted. Anti-
body against murine IL-2 (S4B6) and antibody against the murine
IL-2R
 
a
 
 chain (3C7) were used at 10 
 
m
 
g/ml each. Recombinant
human IL-2 (R&D Systems, Minneapolis, MN) was used at 2 U/
ml. Cells were stimulated for 48 h before 50 
 
m
 
l supernatant was
removed from each well for IL-2 measurement. [
 
3
 
H]-thymidine
was added to cells 72 h after stimulation (1 
 
m
 
Ci in 50 
 
m
 
l medium)
and incubated for 20 h before harvesting using a microtiter plate
cell harvester (Tomtec, Gaithersburg, MD).
 
IL-2 Measurement.
 
IL-2 produced from the cultures was mea-
sured by ELISA or with an IL-2–dependent cell line (CTLL-2).
 
Results
 
Enhanced CD28 Costimulation of TCR Signaling in Itk-neg-
ative T cells.
 
To study CD28 costimulation, CD4
 
1
 
 lymph
node T cells were cultured in microtiter plates coated with
anti-CD3 mAb at suboptimal concentrations. Addition of
soluble anti-CD28 mAb to the culture substantially in-
creased proliferation as well as IL-2 production (Fig. 1),
consistent with previous studies (10, 29, 31). Cells from
Itk-deficient mice also responded to addition of anti-CD28
Ab with increased proliferation and IL-2 secretion, com-
pared with cells stimulated with anti-CD3 alone, or with
anti-CD3 and a control isotype-matched hamster Ab. These
results indicate that Itk is not necessary for CD28 costimu-
lation.
Surprisingly, cells lacking Itk showed consistently higher
proliferation than the control cells from 
 
itk
 
1
 
/
 
2
 
 littermates
or age-matched 
 
itk
 
1
 
/
 
1
 
 mice (Fig. 1 
 
A
 
; data not shown). 
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This increased proliferative response did not correlate with
IL-2 levels produced by the stimulated cells. In the absence
of anti-CD28, no IL-2 was detectable in the culture super-
natant. When anti-CD28 was added to wells coated with
anti-CD3, IL-2 was detected in supernatants of both 
 
itk
 
1
 
/
 
2
 
and 
 
itk
 
2
 
/
 
2
 
 cells, but the level was consistently lower in the
mutant cells, despite their higher proliferative response
(Fig. 1 
 
B
 
).
 
Inhibition of CD28-mediated Costimulation by CTLA-4.
 
Our data indicated that stimulation of CD4
 
1
 
 T cells with
anti-TCR plus anti-CD28 Ab induced stronger prolifera-
tion in the absence than in the presence of Itk. Because
CTLA-4, a cell surface molecule sharing extensive homol-
ogy with CD28, was shown to mediate a negative signal in
T cell activation (32–34), we sought to determine whether
the increased proliferation in the absence of Itk was due to
a lack of negative signaling through CTLA-4. CD4
 
1
 
 T
cells were stimulated by incubation with polystyrene beads
coated with a constant amount of various hamster antibod-
ies. Using beads coated with anti-CD3 and anti-CD28, we
observed that CD28 costimulation occurs in the absence of
Itk (Fig. 2 
 
A
 
), consistent with what was observed with
plate-bound anti-CD3 and soluble anti-CD28 (see Fig. 1 
 
A
 
).
CTLA-4 did not have a positive costimulatory function be-
cause beads coated with anti-CD3 and anti–CTLA-4 did
not stimulate proliferation, and even slightly inhibited anti-
CD3–induced proliferation (Fig. 2 
 
A
 
). As has been re-
ported (32–34), CTLA-4 has a negative effect on the re-
sponse of T cells to stimulation because there was reduced
proliferation upon stimulation with beads coated with anti-
CD3, anti-CD28, and anti–CTLA-4 compared with beads
coated with only anti-CD3 and anti-CD28 (Fig. 2 
 
A
 
). Ad-
dition of anti–CTLA-4 Ab to anti-CD3 and anti-CD28
also reduced the costimulatory effect of anti-CD28 on 
 
itk2/2
Figure 1. CD28 costimulation of TCR-induced proliferation and IL-2
production. (A) CD41 T cells from itk2/2 mice (circles) and itk1/2 litter-
mates (squares) were stimulated with plate-bound anti-CD3 at different
concentrations as indicated, in the presence (solid lines) or absence (broken
lines) of anti-CD28 ascites (1:500). Cell proliferation was measured 48 h
after stimulation. (B) IL-2 production in the culture supernatant after 48 h
of stimulation was measured by ELISA. No detectable IL-2 was produced
from cells stimulated with anti-CD3 alone.
Figure 2. Itk is not required for the inhibitory signal mediated by
CTLA-4. (A) CD41 T cells were stimulated with polystyrene beads
coated with various antibodies as indicated. Cell proliferation was mea-
sured 72 h after stimulation. (B) CD41 T cells from itk2/2 mice (circles)
and itk1/2 littermates (squares) were stimulated with plate-bound anti-
CD3 at different concentrations as indicated, in the presence or absence
of anti-CD28 ascites (1:500). CTLA-4Ig was included at the beginning of
culture (closed symbols) together with anti-CD28. Cell proliferation was
measured 72 h after stimulation.224 CD28 Costimulation in Itk-deficient Mice
cells (Fig. 2 A), suggesting that the inhibitory signal deliv-
ered via CTLA-4 was not affected by the absence of Itk.
It has been shown that activated T cells express B7-1 and
B7-2 (30), which are the ligands for both CD28 and
CTLA-4 (1, 35). Because CTLA-4 has considerably higher
affinity than CD28 for B7-1 and B7-2 (36), it is conceiv-
able that B7 expressed on activated T cells could stimulate
CTLA-4 on these cells. A fusion protein comprised of the
extracellular region of murine CTLA-4 and the Fc region
of human immunoglobulin (CTLA-4Ig) will compete for
B7 binding, thus effectively blocking signaling via CTLA-4
on T cells (30, 34, 37). Addition of CTLA-4Ig to T cells in
anti-CD3–coated wells further increased their proliferation
in response to anti-CD28 (Fig. 2 B), suggesting that
CTLA-4 delivered an inhibitory signal for T cell prolifera-
tion under these conditions. Increased proliferation in re-
sponse to CTLA-4Ig was also observed for stimulated itk2/2
cells (Fig. 2 B). Taken together with the results using anti-
CTLA-4 Ab, we conclude that Itk does not appear to have
a major role in mediating the inhibitory signal from CTLA-4.
The enhanced proliferation observed in the itk2/2 cells in
response to anti-CD28–mediated costimulation therefore is
not due to a defect in inhibitory signaling by CTLA-4.
CD28 Costimulation in the Presence of Phorbol Esters. To
determine whether the observed enhancement in costimu-
lation is due to changes in relevant cell surface receptors,
FACSÒ analysis was performed with antibodies specific for
CD28, CTLA-4, CD25, and CD69 before and after co-
stimulation. There was no significant difference in levels of
expression of these molecules in itk1/2 versus itk2/2 cells
(data not shown). However, the level of CD3 on itk2/2
cells was found to be consistently lower (less than twofold)
Figure 3. Opposite functions of Itk in CD28 costimulation– and TCR stimulation–induced proliferation. (A) CD41 T cells were stimulated with
PMA (10 ng/ml) in the presence or absence of anti-CD28 or anti-CD3 as indicated. The immunosuppressive agent drug FK506 was used at 100 ng/ml.
Cell proliferation was measured 72 h after stimulation. a-CD28, purified anti-CD28 mAb (2.5 mg/ml); a-CD3, purified anti-CD3 mAb (2.5 mg/ml). (B)
CD41 T cells were stimulated with PMA (10 ng/ml) in the presence of different concentrations of purified anti-CD28 mAb as indicated. FK506 was
used at 100 ng/ml. Cell proliferation was measured 72 h after stimulation. (C) CD41 T cells were stimulated with PMA (10 ng/ml) in the presence of
different concentrations of purified anti-CD3 mAb as indicated. FK506 was used at 100 ng/ml. Cell proliferation was measured 72 h after stimulation.
(D) CD41 T cells were stimulated with PMA (10 ng/ml) and ionomycin (125 ng/ml) in the presence or absence of anti-CD28 or anti-CD3 as indicated.
Cell proliferation was measured 72 h after stimulation. IONO, ionomycin (125 ng/ml); a-CD28, purified anti-CD28 mAb (2.5 mg/ml); and a-CD3, pu-
rified anti-CD3 (2.5 mg/ml).225 Liao et al.
than on itk1/2 cells from control littermates. This differ-
ence in CD3 levels is unlikely to account for the increased
proliferation of itk2/2 cells induced with anti-CD3 and
anti-CD28, because in the presence of anti-CD28 itk2/2
cells showed a stronger proliferative response than itk1/2
cells over a range of anti-CD3 concentrations. We showed
previously that in the absence of Itk the efficiency of TCR
signaling is reduced (27). However, it remains possible that
the increased proliferation of itk2/2 cells upon costimula-
tion is due to an indirect consequence of reduced TCR
signaling.
To address this issue, we attempted to reveal the effect of
Itk on CD28 costimulation in the context of a minimal and
defined contribution from the TCR signaling pathway. Pre-
vious studies using highly purified human or mouse T cells
have shown that anti-CD28 augments proliferation in cells
stimulated with the phorbol ester PMA, whereas PMA alone
does not induce proliferation (31, 38). Stimulation of freshly
isolated CD41 lymph node cells with anti-CD28 in the
presence of PMA greatly augmented cell proliferation (Fig.
3 A). In this assay, cells from the Itk-deficient mice dis-
played 5–10-fold greater thymidine incorporation than cells
from control littermates expressing Itk (Fig. 3 A). In addi-
tion, titration of anti-CD28 antibodies suggests that the loss
of Itk does not simply result in a shift of sensitivity to
CD28 stimulation, because the proliferative response of the
itk1/1 cells to high concentrations of Ab remains low when
compared with itk2/2 cells stimulated with much lower con-
centrations of anti-CD28 (Fig. 3 B). As a control, CD41
T cells were treated with purified anti-CD3 Ab and PMA.
Consistent with previous studies (27), cells from the Itk-
deficient mice had severely impaired proliferative responses
(Fig. 3, A and C).
A hallmark of CD28-mediated signal transduction is its
resistance to immunosuppressive agents such as cyclosporin
A (CsA) and FK506 (31, 39). The proliferative responses of
wild-type and itk2/2 cells to anti-CD28 with PMA were
relatively resistant to FK506 (Fig. 3, A and B). This is in
contrast with proliferation in response to anti-CD3, which
was completely abolished by FK506 (Fig. 3, A and C). To-
gether, these results indicate that augmentation of prolifer-
ation with anti-CD28 in the absence of Itk is occurring
uniquely through the CD28 costimulation pathway. Re-
markably, in the absence of Itk, the calcineurin-independent
CD28 signaling pathway is enhanced, whereas calcineurin-
dependent TCR signaling is severely compromised.
Activation of the TCR signaling pathway can be effec-
tively mimicked by treating T cells with PMA and iono-
mycin. Cells from itk1/1 and itk2/2 mice proliferate equally
well in the presence of PMA and ionomycin (Fig. 3 D; ref-
erence 27), indicating that the TCR signaling deficit in the
mutant mice lies proximal to the effects of these agents. Be-
cause CD28 costimulation is also observed in the presence
of PMA and ionomycin (31, 40), we sought to use this reg-
imen to substitute for the TCR signal, thus bypassing the
involvement of Itk in this pathway. In the presence of
PMA and ionomycin, anti-CD28 treatment resulted in en-
hanced proliferation of T cells from both itk2/2 and itk1/1
mice (Fig. 3 D). Proliferation of cells from the mutant mice
was potentiated to a greater extent in comparison to nega-
tive littermates, but the effect was modest when compared
with that observed with PMA and anti-CD28 stimulation.
Roles of IL-2 in Cell Proliferation Induced with Anti-TCR
and Anti-CD28. CD28 costimulation has been shown to
result in increased cytokine levels through increased tran-
scription as well as mRNA stabilization (2, 41, 42). Pro-
duction of cytokines such as IL-2, as a consequence of T cell
activation, further stimulates T cell proliferation by way of
an autocrine mechanism. In the experiments described above,
we were unable to identify a correlation between the ex-
tent of cell proliferation and of IL-2 production in response
to costimulation (see Fig. 1 B; data not shown). It is possi-
ble that IL-2 produced in these cultures was consumed
during cell proliferation. To address whether enhanced
CD28 costimulation of itk2/2 cells may be dependent on
IL-2, we studied cell proliferation in the presence of block-
ing antibodies.
When a mixture of antibodies against murine IL-2 and
murine IL-2 receptor were added to CD41 T cells stimu-
lated with anti-CD28 and increasing amounts of plate-bound
anti-CD3, proliferation of both itk1/2 and itk2/2 cells was
abolished (Fig. 4). This result suggests that proliferation in
Figure 4. Cell proliferation induced by
TCR and CD28 is dependent on IL-2.
CD41 T cells from itk2/2 mice and itk1/2
littermates were stimulated with plate-bound
anti-CD3 at different concentrations as indi-
cated, in the presence or absence of anti-
CD28 ascites (1:500). Anti-CD28 and anti-
murine IL-2 were added with anti-murine
IL-2R or with recombinant human IL-2 at
the beginning of culture. Cell proliferation
was measured 72 h after stimulation.
a-CD28, anti-CD28 ascites; a-mIL2, anti-
murine IL-2 mAb; a-mIL2R, anti-murine
IL-2Ra mAb; and hIL-2, recombinant hu-
man IL-2.226 CD28 Costimulation in Itk-deficient Mice
response to costimulation is dependent on IL-2 and that
the contribution of other cytokines to cell proliferation is
minimal in this system.
To determine whether itk1/2 and itk2/2 cells have in-
trinsic differences in their response to IL-2 after stimulation
with anti-CD3 and anti-CD28, recombinant human IL-2
was added to the culture together with antibody against
murine IL-2. Both itk1/2 and itk2/2 cells responded to the
addition of recombinant IL-2 with enhanced proliferation,
especially at low anti-CD3 concentrations (Fig. 4). The dif-
ference in proliferation between itk2/2 and itk1/2 cells still
persisted in the presence of human IL-2, suggesting that
itk2/2 cells have a better response to IL-2 compared with
itk1/2 cells under these conditions. T cell activation in-
creased CD25 expression on both itk2/2 and itk1/2 cells.
However, we did not observe any consistent difference of
CD25 expression between itk2/2 and itk1/2 cells (data not
shown).
Discussion
In this study, we examined the role of the nonreceptor
protein tyrosine kinase Itk in regulating costimulatory sig-
naling through CD28. Under several conditions investi-
gated, mature T cells from Itk-deficient mice had a much
stronger proliferative response upon CD28 costimulation
than cells from control littermates expressing Itk or from
age-matched wild-type mice. However, the level of IL-2
was consistently lower in Itk2 cells compared with Itk1 cells
under these culture conditions. In cells stimulated with
limiting amounts of anti-CD3 plus anti-CD28, prolifera-
tion was dependent on IL-2 and IL-2 receptor. However,
the differential proliferation between mutant and wild-type
cells was retained when an equivalent amount of human
IL-2 was added to cells treated with anti-mouse IL-2. This
suggests that the Itk2 cells have increased sensitivity to IL-2
receptor–mediated signaling. Taken together, these results
suggest that, in the absence of Itk, there is an enhancement
in CD28-dependent processing of signals that result in cell
cycle progression. The nature of the signals involved re-
mains unclear. We have shown that it is not due to a lack
of the inhibitory signal mediated by CTLA-4 (Fig. 2), nor
to a difference in activation-induced cell death (data not
shown).
Itk is a member of a small family of protein tyrosine ki-
nases, which also includes Btk and Tec. In the absence of
Btk, B cell development is impaired, as is proximal signal
transduction through the B cell antigen receptor (43, 44).
Itk is similarly required for effective signaling and prolifera-
tion following antibody cross-linking of the TCR complex
(27). Thus, Itk and Btk appear to contribute to similar sig-
naling mechanisms after ligation of the antigen receptor
complexes on T and B cells, respectively. The signaling de-
fects of the antigen receptors in cells lacking Itk or Btk can
be overcome by stimulation with phorbol esters and cal-
cium ionophore, indicating that these protein tyrosine ki-
nases function at an early juncture in the signal transduction
pathways.
Itk has been previously implicated in CD28 costimula-
tion because it can be coprecipitated with CD28 (28, 45).
The results of this study suggest that association of Itk with
CD28 is not required for signal transduction, but may, in-
stead, downregulate CD28-derived signals. The mecha-
nism of such downregulation remains unclear. It does not
involve regulation of cell surface expression of CD28,
which is similar in itk1/1, itk1/2, and itk2/2 cells (data not
shown). It is possible that association of Itk with CD28 in-
terferes with signal transduction by changing the conforma-
tion of CD28 or by preventing other signaling molecules
from interacting with CD28. Alternatively, Itk could acti-
vate or inhibit a downstream effector of CD28 signaling.
The interplay between the TCR and CD28 signaling
pathways may provide some clues regarding the mecha-
nism of action of Itk. Itk appears to regulate the TCR and
CD28 signaling pathways in opposite fashion. A major dis-
tinction between these pathways is their relative depen-
dence on calcineurin, exhibited as sensitivity to immuno-
suppressive agents such as CsA and FK506 (31, 38, 40).
CD28-induced cell proliferation persists in the presence of
FK506, whereas proliferation in response to anti-CD3 is
completely abolished (Fig. 3; references 31, 39). The en-
hanced CD28-mediated proliferation of itk2/2 cells re-
mains resistant to FK506, suggesting that Itk regulates a
specific step in CD28 signaling, before it converges with
the TCR signaling pathway.
The intersection of the TCR and CD28 signaling path-
ways remains poorly understood. One recent study (46)
suggests that integration of the CD28 costimulatory signal
and the TCR signaling pathway occurs at the level of acti-
vation of the c-Jun NH2 terminus kinase (JNK). JNK be-
longs to the mitogen-activated protein kinase family of serine/
threonine kinases. Stimulation of T cells with PMA and
anti-CD28 activates JNK, whereas either alone has no ef-
fect (46). Despite the differences in proliferation of mutant
and wild-type T cells after treatment with PMA and anti-
CD28, we failed to observe any difference in activation of
JNK between itk2/2 and itk1/1 cells (data not shown).
CD28 and T Cell Maturation. CD28 is highly expressed
on developing thymocytes (31). In addition, there appears
to be tissue-restricted expression of B7 family members on the
thymic epithelia and dendritic cells within the corticomed-
ullary and medullary regions of the thymus (47, 48). The
importance of CD28 in T cell development has been sug-
gested from experiments which showed that negative selec-
tion of CD41CD81 thymocytes may involve CD28 co-
stimulation (49). This issue has been further addressed using
mice defective in CD28 expression. Although these mice
did not display any obvious developmental phenotype,
CD282/2 T cells showed a selective disadvantage compared
with CD281 T cells in mixed bone marrow chimeras (50).
Itk-deficient mice exhibit defects in T cell maturation
(27). There are reduced numbers of T cells, particularly
CD41 cells. Studies in mice expressing transgenic TCRs in
the Itk-deficient background suggest that Itk may be im-
portant for positive selection of thymocytes. The develop-
mental phenotype of Itk-deficient mice thus may be ex-227 Liao et al.
plained by a reduction in TCR signaling in the absence of
Itk. However, there are intriguing observations suggesting
that Itk may reduce signaling in potentially autoreactive
cells. In mice expressing the transgenic AND TCR, lack of
Itk resulted in accumulation of CD42CD82 mature T cells
expressing the transgenic TCR (27). Double-negative (CD42
CD82) T cells have been previously observed in transgenic
mice that express a self-reactive transgenic TCR (51). These
cells may be under selective pressure to reduce the avidity
of TCR interaction with MHC by turning off expression
of the CD4 coreceptor. This suggests that, at a certain stage
in T cell maturation, lack of Itk may actually increase the
strength of the signal through the TCR complex and
CD28. The inhibitory function of Itk in CD28 costimula-
tion thus may provide a mechanistic explanation for the ab-
normal T cell development observed in the Itk2 mice.
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